Key result
Anti-HAV seroprevalence reaches ~66% in healthy southern Iranians and is significantly linked to advancing age.
Why the study?
The prevalence of hepatitis A virus and hepatitis E virus infections varies geographically and was not determined among healthy individuals in southern Iran.
What is the seroprevalence of HAV and HEV infections among healthy individuals in southern Iran?
Cross-Sectional (n=1,030)
What is the seroprevalence of HAV and HEV infections among healthy individuals in southern Iran?
The prevalence of HAV and HEV antibodies in southern Iran is high and positively correlated with age, suggesting a potential benefit for HAV vaccination in antibody-negative adults.
Answers are grounded in this paper and cite their sources.
Informs regional HAV/HEV epidemiology in southern Iran; leaves open prevention strategies pending prospective data.
BACKGROUND: Enterically-transmitted acute viral hepatitis is caused predominantly by hepatitis A virus (HAV) and hepatitis E virus (HEV). The prevalence of HEV and HAV infections varies in different geographical regions. OBJECTIVES: This study was conducted to determine the prevalence of HEV and HAV infections among Iranian healthy individuals in southern Iran. PATIENTS AND METHODS: Totally, 1030 samples were collected from healthy subjects in schools, those referred to tertiary outpatient clinics and health centers in Shiraz between November 2011 and May 2012. Their ages ranged between six months and 95 years. The presence of total anti-HAV and anti-HEV immunoglobulin M (IgM) in plasma was assessed by ELISA. RESULTS: The results showed that 66.2% and 0.6% of the general population in this area were positive for total anti-HAV and IgM antibodies by ELISA, respectively. As seen, 13.4% and 0.9% were positive for total anti-HEV and IgM antibodies, respectively. The difference in total anti-HAV and anti-HEV antibodies was significant among the age groups (P < 0.001). CONCLUSIONS: This study showed that the prevalence rates of HAV and HEV antibodies were positively correlated with age. The results demonstrated that the infection with these two viruses in the region was high and some high-risk individuals including females at child-bearing age were more susceptible. HAV vaccination could be recommended for antibody-negative adults.
No takes yet. Share an insight, caveat, or question.
Asaei et al. (2015) conducted a cross-sectional in Healthy (n=1,030). Endemic exposure to HAV and HEV was evaluated on Seroprevalence of total anti-HAV antibodies. In a healthy population in southern Iran, the seroprevalence of total anti-HAV and anti-HEV antibodies was 66.2% and 13.4%, respectively, with prevalence significantly increasing with age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: